The effectiveness of current treatments for melanoma, the deadliest form of skin cancer, could be improved by using approaches that wipe out the ‘survival system’ of cancer cells according to a study published today in Nature Communications.*
Researchers from the Babraham Institute, AstraZeneca and the Cancer Research UK Cambridge Centre have demonstrated an approach, used in parallel with existing treatments, which knocks out one of melanoma cells’ survival pathways, and is effective at triggering tumour cell death and delaying treatment resistance.
The researchers suggest this approach may also help to tackle late stage cancers even after they have become resistant to existing treatments.
There are around 16,000 new melanoma skin cancer cases in the UK every year. Although survival has doubled in the UK in the past 40 years, late-stage melanoma is aggressive and difficult to treat. Around 55% of people with latest stage melanoma survive their disease for 1 year or more compared to nearly 100% of those diagnosed at the earliest stage.** These late-stage cancers evolve rapidly to resist treatment.
Cancer cells can rely on various ‘survival proteins’ to stay alive despite the effect of treatment. But so far, researchers have been unable to pinpoint which of these survival proteins are used by melanoma cells.
Researchers from the Babraham Institute and Cancer Research UK Cambridge Centre discovered that melanoma cells rely on a protein called MCL1, which is critical for the cells to survive when they are exposed to standard MEK and BRAF inhibitor drugs such as trametinib or vemurafenib.
The researchers then studied an investigational compound from AstraZeneca, a MCL1 antagonist called AZD5991, and used it in the lab against models of melanoma.
They showed that by blocking MCL1, AZD5991 inactivated the backup survival system within melanoma cells. Combining AZD5991 with a treatment like vemurafenib had a ‘double whammy’ effect against cancer cells, eliminating them more effectively.
This drug combination also worked in late-stage melanoma tumours, derived from patients and grown in mice. In these mice, combinations of vemurafenib and AZD5991 reduced the size of tumours, sometimes almost completely, and slowed their growth compared to standard treatment alone. However, used alone, AZD5991 had no effect in these models.
Patients with these aggressive tumours may be given a different type of drug called an ERK inhibitor; although these drugs are still undergoing clinical trials and not widely available yet, it already seems that melanoma could evolve rapidly to resist them. Future clinical trials could look at whether blocking MCL1 at the same time as giving an ERK inhibitor, could halt the evolution of these late-stage tumours from becoming resistant.
Dr Mathew Sale, from the Babraham Institute, said: “This study has demonstrated that melanoma cells are addicted to the MCL1 protein for survival, but only when they are treated with the existing melanoma drugs. By targeting both vulnerabilities at the same time we can kill melanoma cells, causing greater inhibition of tumour growth over a longer time period.”
Dr Simon Cook, group leader at the Babraham Institute, said: “This study stems from 15 years of basic research in which we have sought to understand the normal signals that control whether a cell lives or dies. However, we became increasingly aware that these same pathways were not functioning correctly in cancer. Thanks to a long-standing partnership with AstraZeneca and the Cancer Research UK Cambridge Centre we were able to translate this basic research to understand and potentially better treat melanoma.”
Professor Duncan Jodrell from the Cancer Research UK Cambridge Centre, who contributed to the research, said: “This work highlights the importance of performing collaborative research like this, as it could lead to new ways to tackle cancers, particularly those that are hard to treat. Our work also shows the value of scientists in basic science labs working closely with drug development specialists and industry scientists, which is fundamental if we want to find better treatments for people affected by cancer.”
** Based on one-year age-standardised net cancer survival by stage, adults (aged 15-99 years), diagnosed between 2013 and 2017 in England.
* Publication reference
Sale et al. Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications. DOI: 10.1038/s41467-019-12409-w
Media enquiries contacts:
Daimona Kounde in the Cancer Research UK press office on 020 3469 5128 or, the out of hours press officer on 07050 264 059.
Dr Louisa Wood, Communications Manager, Babraham Institute, email@example.com, 01223 496230
Cell cultures in an incubator: Cancer cells being grown for research at the Babraham Institute.
Affiliated authors (in author order):
Dr Matthew Sale - former PhD student and AZ-funded postdoc in the Cook lab
Emma Minihane - PhD student, Cook lab
Rebecca Gilley - senior research associate, Cook group
Dr Eiko Ozono - former postdoc in the Cook labDr Simon Cook, group leader, Signalling programme
This study was funded by an AstraZeneca-Cambridge Cancer Centre Collaborative Award, Cancer Research UK grants, a Cambridge Trusts PhD studentship and AstraZeneca. The Institute's Signalling programme receives strategic funding from an Institute Strategic Programme grant from UKRI - Biotechnology and Biological Sciences Research Council.
Press release: Tumour cells’ drug addiction may be their downfall, 2nd May 2019Research pages of the Cook group: Signalling research programme
Feature article: Making the Most of Signalling Research, Annual Research Report 2017 (view report)
As a publicly funded research institute, the Babraham Institute is committed to engagement and transparency in all aspects of its research. Animals are only used in Babraham Institute research when their use is essential to address a specific scientific goal, which cannot be studied through other means. The main species used are laboratory strains of rodents, with limited numbers of other species. We do not house cats, dogs, horses or primates at the Babraham Research Campus for research purposes.
This research used mice to grow human-derived tumours to study cell growth. Please follow the link for further details of the Institute’s animal research and our animal welfare practices.
About Cancer Research UK
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow Cancer Research UK on Twitter and Facebook.
About the Babraham Institute
The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.
14 November 2019